Page 1 | Search Results | Diabetes | American Diabetes Association

1-13 of 13

Sort by

Sort Order Select

Meeting Abstracts

674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD

VICTORIA E. PARKER, THUONG HOANG, HEIKE SCHLICHTHAAR, FRASER W. GIBB, BARBARA WENZEL, MAXIMILIAN G. POSCH, YI-TING CHANG, MARCELLA PETRONE, LARS HANSEN, PHILIP AMBERY, HIDDO L. HEERSPINK, RORY J. MCCRIMMON, LUTZ JERMUTUS

Diabetes 2021;70(Supplement_1):674-P

https://doi.org/10.2337/db21-674-P

Published: 01 June 2021

View article titled, 674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD

Meeting Abstracts

105-OR: An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Cotadutide on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus

RAJNA GOLUBIC, JANE KENNET, VICTORIA E. PARKER, DARREN ROBERTSON, DAN LUO, LARS HANSEN, LUTZ JERMUTUS, PHILIP AMBERY, ADRIAN PARK, MARK EVANS

Diabetes 2021;70(Supplement_1):105-OR

https://doi.org/10.2337/db21-105-OR

Published: 01 June 2021

View article titled, 105-OR: An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Cotadutide on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus

Meeting Abstracts

354-OR: Cotadutide (medi0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content

DARREN ROBERTSON, LARS HANSEN, PHILIP AMBERY, RUSSELL L. ESTERLINE, LUTZ JERMUTUS, YI-TING CHANG, MARCELLA PETRONE, EDVIN JOHANSSON, LARS JOHANSSON, FOLKE B. SJÖBERG, VICTORIA PARKER

Diabetes 2020;69(Supplement_1):354-OR

https://doi.org/10.2337/db20-354-OR

Published: 01 June 2020

View article titled, 354-OR: Cotadutide (medi0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content

Meeting Abstracts

951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM

DARREN ROBERTSON, LARS HANSEN, MEENA JAIN, VICTORIA PARKER, MARCELLA PETRONE, TAO WANG, TIM HEISE, LUTZ JERMUTUS

Diabetes 2020;69(Supplement_1):951-P

https://doi.org/10.2337/db20-951-P

Published: 01 June 2020

View article titled, 951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM

Meeting Abstracts

1800-P: Cotadutide, a GLP-1/GCG Receptor Co-Agonist, Improves Insulin Sensitivity and Restores Normal Insulin Secretory Capacity in DIO Mice

RHIANNA C. LAKER, LOUISE LANTIER, OWEN MCGUINNESS, SARAH WILL, KYLE KUSZPIT, ALEX R. ALFARO, LUTZ JERMUTUS, CHRISTOPHER J. RHODES

Diabetes 2020;69(Supplement_1):1800-P

https://doi.org/10.2337/db20-1800-P

Published: 01 June 2020

View article titled, 1800-P: Cotadutide, a GLP-1/GCG Receptor Co-Agonist, Improves Insulin Sensitivity and Restores Normal Insulin Secretory Capacity in DIO Mice

Meeting Abstracts

1010-P: Effects of MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, on Amino Acids, Ketones, and Free Fatty Acids

VICTORIA E. PARKER, DARREN ROBERTSON, TAO WANG, DAVID C. HORNIGOLD, MAXIMILIAN G. POSCH, LEONA PLUM-MOERSCHEL, JURIS J. MEIER, HEIKE SCHLICHTHAAR, BEATE M. KLAUS, LUTZ JERMUTUS, PHILIP AMBERY, BOAZ HIRSHBERG

Diabetes 2019;68(Supplement_1):1010-P

https://doi.org/10.2337/db19-1010-P

Published: 01 June 2019

View article titled, 1010-P: Effects of MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, on Amino Acids, Ketones, and Free Fatty Acids

Meeting Abstracts

988-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time

DARREN ROBERTSON, VICTORIA E. PARKER, PHILIP AMBERY, MARCELLA PETRONE, TAO WANG, TIM HEISE, LEONA PLUM-MOERSCHEL, LUTZ JERMUTUS, BOAZ HIRSHBERG, JURIS J. MEIER

Diabetes 2019;68(Supplement_1):988-P

https://doi.org/10.2337/db19-988-P

Published: 01 June 2019

View article titled, 988-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time

Meeting Abstracts

1883-P: Phosphoproteomics Reveals Mechanistic Insight into Glucagon-Mediated Inhibition of Hepatic Lipogenesis and How MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Reverses Steatosis

RHIANNA C. LAKER, MICHELLE BOLAND, ARKADIUSZ NAWROCKI, KARLY M. MATHER, LUTZ JERMUTUS, MARTIN R. LARSEN, JAMES TREVASKIS, CHRISTOPHER J. RHODES

Diabetes 2019;68(Supplement_1):1883-P

https://doi.org/10.2337/db19-1883-P

Published: 01 June 2019

View article titled, 1883-P: Phosphoproteomics Reveals Mechanistic Insight into Glucagon-Mediated Inhibition of Hepatic Lipogenesis and How MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Reverses Steatosis

Meeting Abstracts

Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes

PHILIP AMBERY, MICHAEL W. STUMVOLL, MAXIMILIAN G. POSCH, TIM HEISE, LEONA PLUM-MOERSCHEL, LAN-FENG TSAI, DARREN ROBERTSON, MARCELLA PETRONE, CRISTINA RONDINONE, VICTORIA E. PARKER, BOAZ HIRSHBERG, LUTZ JERMUTUS

Diabetes 2018;67(Supplement_1):1067-P

https://doi.org/10.2337/db18-1067-P

Published: 01 July 2018

View article titled, Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes

Meeting Abstracts

MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes—A Multiple-Ascending-Dose Study

DARREN ROBERTSON, MICHAEL W STUMVOLL, MAXIMILIAN G POSCH, TIM HEISE, LEONA PLUM-MOERSCHEL, GERNOT KLEIN, LAN-FENG TSAI, MARCELLA PETRONE, BOAZ HIRSHBERG, CRISTINA RONDINONE, VICTORIA E PARKER, LUTZ JERMUTUS, PHILIP AMBERY

Diabetes 2018;67(Supplement_1):1070-P

https://doi.org/10.2337/db18-1070-P

Published: 01 July 2018

View article titled, MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes—A Multiple-Ascending-Dose Study

Meeting Abstracts

MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH

MICHELLE BEATON, SILVIA GUIONAUD, JAMES P. CONWAY, JOE GRIMSBY, CHRISTOPHER J. RHODES, LUTZ JERMUTUS, JAMES TREVASKIS

Diabetes 2018;67(Supplement_1):1841-P

https://doi.org/10.2337/db18-1841-P

Published: 01 July 2018

View article titled, MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH

Meeting Abstracts

Effects of MEDI0382 on Pancreatic and Incretin Hormones

VICTORIA E.R. PARKER, LAN-FENG TSAI, DARREN ROBERTSON, MARCELLA PETRONE, CRISTINA RONDINONE, BOAZ HIRSHBERG, LUTZ JERMUTUS, PHILIP AMBERY

Diabetes 2018;67(Supplement_1):79-OR

https://doi.org/10.2337/db18-79-OR

Published: 01 July 2018

View article titled, Effects of MEDI0382 on Pancreatic and Incretin Hormones

Journal Articles

Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats

Diabetes 2017;66(7):2007–2018

https://doi.org/10.2337/db16-0916

Published: 13 April 2017

View article titled, Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats

Includes: Supplementary data

NARROW

674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD

105-OR: An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Cotadutide on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus

354-OR: Cotadutide (medi0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content

951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM

1800-P: Cotadutide, a GLP-1/GCG Receptor Co-Agonist, Improves Insulin Sensitivity and Restores Normal Insulin Secretory Capacity in DIO Mice

1010-P: Effects of MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, on Amino Acids, Ketones, and Free Fatty Acids

988-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time

1883-P: Phosphoproteomics Reveals Mechanistic Insight into Glucagon-Mediated Inhibition of Hepatic Lipogenesis and How MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Reverses Steatosis

Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes

MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes—A Multiple-Ascending-Dose Study

MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH

Effects of MEDI0382 on Pancreatic and Incretin Hormones

Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only